Blood and tissue collection for immunological tests in soft tissue sarcoma treatment
Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas
This study is collecting blood and tissue samples from adults with high-risk soft tissue sarcoma who are receiving treatment to see how their immune system and tumors respond to the therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Tuebingen Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Tübingen, Baden-Wurttemberg) |
| Trial ID | NCT06385288 on ClinicalTrials.gov |
What this trial studies
This study involves collecting blood and tissue samples from adult patients with high-risk soft tissue sarcoma undergoing neoadjuvant therapy, which includes radiotherapy and possibly chemotherapy and hyperthermia. The aim is to analyze these samples to understand the immunological response and tumor characteristics before and after treatment. Patients will undergo advanced imaging and their tumor cells will be cultured for further biological analysis. The study seeks to enhance the understanding of treatment responses and immune interactions in soft tissue sarcomas.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years with histologically confirmed high-risk soft tissue sarcoma who are eligible for neoadjuvant multimodal therapy.
Not a fit: Patients under 18 years or those with poor understanding or lack of ability to consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with soft tissue sarcomas.
How similar studies have performed: While similar studies have explored immunological responses in cancer treatment, this specific approach combining neoadjuvant therapy with extensive immunological analysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Planned histological confirmation for especially high-risk soft tissue sarcoma via open Sampling * Indication for neoadjuvant multimodal therapy (radiation and locoregional Hyperthermia, optionally with simultaneous chemotherapy) * Planned resection of a department of the CWS * Age \> 18 years * Ability to consent * Additionally for imaging study: Treatment on the combined MR hyperthermia device Exclusion Criteria: * Age \< 18 years * Poor understanding (language etc.) * Lack of reconnaissance ability
Where this trial is running
Tübingen, Baden-Wurttemberg
- University Hospital Tuebingen — Tübingen, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Study coordinator: Franziska Eckert, MD, Prof.
- Email: franziska.eckert@med.uni-tuebingen.de
- Phone: +49 7071 29
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.